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Cytoplasmic FLIP(S) and nuclear FLIP(L)
mediate resistance of castrate-resistant
prostate cancer to apoptosis induced
by IAP antagonists
Christopher McCann1, Nyree Crawford 1, Joanna Majkut1, Caitriona Holohan1, Chris W. D. Armstrong1,
Pamela J. Maxwell1, Chee Wee Ong 1, Melissa J. LaBonte1, Simon S. McDade1, David J. Waugh1 and
Daniel B. Longley1
Abstract
Expression of tumor necrosis factor-α (TNFα) in the serum of prostate cancer patients is associated with poorer
outcome and progression to castrate-resistant (CRPC) disease. TNFα promotes the activity of NFκB, which regulates a
number of anti-apoptotic and proinﬂammatory genes, including those encoding the inhibitor of apoptosis proteins
(IAPs); however, in the presence of IAP antagonists, TNFα can induce cell death. In the presence of recombinant or
macrophage-derived TNFα, we found that IAP antagonists triggered degradation of cIAP1 and induced formation of
Complex-IIb, consisting of caspase-8, FADD and RIPK1 in CRPC models; however, no, or modest levels of apoptosis
were induced. This resistance was found to be mediated by both the long (L) and short (S) splice forms of the caspase-
8 inhibitor, FLIP, another NFκB-regulated protein frequently overexpressed in CRPC. By decreasing FLIP expression at
the post-transcriptional level in PC3 and DU145 cells (but not VCaP), the Class-I histone deacetylase (HDAC) inhibitor
Entinostat promoted IAP antagonist-induced cell death in these models in a manner dependent on RIPK1, FADD and
Caspase-8. Of note, Entinostat primarily targeted the nuclear rather than cytoplasmic pool of FLIP(L). While the
cytoplasmic pool of FLIP(L) was highly stable, the nuclear pool was more labile and regulated by the Class-I HDAC
target Ku70, which we have previously shown regulates FLIP stability. The efﬁcacy of IAP antagonist (TL32711) and
Entinostat combination and their effects on cIAP1 and FLIP respectively were conﬁrmed in vivo, highlighting the
therapeutic potential for targeting IAPs and FLIP in proinﬂammatory CRPC.
Introduction
Inﬂammation contributes towards the initiation and
progression of prostate cancer1, with levels of inﬂamma-
tory cytokines, such as tumor necrosis factor-alpha
(TNFα), correlating with poor outcome and progression
to castrate-resistant disease (CRPC)2,3. TNFα derived
from cells in the tumor microenvironment can activate
proinﬂammatory and pro-survival pathways in tumor
cells, such as those mediated by the NFκB transcription
factor family. Binding of TNFα to TNF-receptor 1
(TNFR1) results in formation of Complex-I, which con-
tains receptor-interacting protein kinase-1 (RIPK1) and
the cellular inhibitors of apoptosis proteins-1/2 (cIAP1/2).
Within Complex-I, RIPK1 ubiquitination is mediated by
cIAP1/2, subsequently leading to activation of NFκB4.
Transcribed NFκB target genes, including those encoding
anti-apoptotic proteins, such as cIAP1/2 and FLIP, and
inﬂammatory cytokines, such as IL-8 and TNFα itself, act
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to further potentiate localized inﬂammation and cell
survival5. In a previous study, we demonstrated that FLIP
expression is elevated in CRPC and antagonizes response
to androgen receptor-targeted therapy6.
Therapeutic IAP antagonists, such as TL32711 (Bir-
inapant), have been developed based on the IAP-binding
motif (Ala-Val-Pro-Ile) of the endogenous inhibitor of
IAPs – SMAC (Second Mitochondrial-Derived Acti-
vator of Caspases) – and interact with the structurally
conserved BIR (baculovirus IAP repeat) domains of
IAPs7. IAP antagonist binding to the BIR domains of
cIAP1 induce dimerization of its RING domains, sti-
mulating E3-Ubiquitin ligase activity and subsequent
auto-ubiquitination and proteasomal degradation of
cIAPs8. cIAP1 depletion following IAP antagonist
treatment leads to formation of a cytoplasmic cell death-
regulating platform termed Complex-IIb, consisting of
RIPK1, FADD and procaspase-89. Procaspase-8 homo-
dimerization at this complex results in its processing
and activation, leading to downstream activation of
caspases-3/7. Hetero-dimerization of procaspase-8 with
either the long (FLIP(L)) or short (FLIP(S)) splice forms
of FLIP in Complex-IIb inhibits procaspase-8 processing
and therefore induction of apoptosis10. IAP antagonists
can also disrupt the interaction between XIAP and
caspases-3, -7 and -911,12, thus relieving XIAP-mediated
repression of these caspases and promoting the execu-
tion phase of apoptosis13.
TL32711 is a bivalent IAP antagonist which initially
appeared promising in Phase1/2 clinical trials, but was
later revealed to offer minimal clinical beneﬁt to
patients as a single agent and may act best alongside
chemotherapeutic agents14,15. This has paved the way
for the development of more potent IAP antagonists
with improved bioavailability. The monovalent IAP
antagonist ASTX660 is a non-peptidomimetic agent
generated by structure-based design with potent on-
target activity and favourable tolerability proﬁle com-
pared to bivalent peptide mimetic IAP antagonists and is
currently in clinical development (Phase 1/2)16. In this
study, we tested the hypothesis that proinﬂammatory,
TNFα-rich, CRPC3 would be highly sensitive to IAP
antagonists, as these agents convert this proin-
ﬂammatory, anti-apoptotic cytokine into a cell death-
inducing ligand.
Materials and methods
Compounds
TL32711 and Entinostat were obtained from Selleck
Chemicals (Newmarket, UK), ASTX660 was obtained
from Astex Pharmaceuticals (Cambridge, UK), z-
VAD-fmk and Necrostatin-1 were purchased from
Sigma-Aldrich (Gillingham, UK), GSK’874 and Necro-
sulfonamide from Merck (Darmstadt, Germany),
recombinant TNFα from Alomone Labs (Israel), TNFα-
neutralising antibody from Cell Signaling Technologies
(Danvers, MA, USA) and Leptomycin-B solution was
purchased from Sigma-Aldrich.
Cell lines
PC3, DU145, VCaP and THP-1 cells were obtained
from American Type Culture Collection (ATCC, Mana-
ssas, VA, USA) PC3, DU145 and THP-1 cells were cul-
tured in RPMI medium (Invitrogen, Paisley, UK) with 10%
fetal bovine serum (Invitrogen), and VCaP cells were
cultured in DMEM (ATCC, LGC Standards, Middlesex,
UK) with 10% fetal bovine serum.
Generation of overexpressing cell lines
PC3 cell lines overexpressing wild-type and mutant
FLIP spliceforms were generated as previously
described17.
Generation of PC3 CRISPR caspase-8 cell lines
PC3 CRISPR caspase-8 cells were generated by retro-
viral infection with pLentiCRISPRV2 with guide RNA
AAGTGAGCAGATCAGAATTG which was provided as
a kind gift from Prof. Galit Lahav, as described pre-
viously18. A mixed colony of cells was established fol-
lowing selection in Puromycin.
Macrophage polarisation and conditioned-media
collection
THP1 cells were differentiated to M1 polarised macro-
phages by 6 h treatment with 320 nM Phorbol 12-
myristate 13-acetate (Sigma-Aldrich), followed by 18 h
with 100 ng/mL Lipopolysaccharide (Sigma-Aldrich) and
20 ng/mL Interferon-γ. Conditioned media was collected
after 24 h and incubated for 1 h with 100 ng/mL TNFα
neutralizing antibody (Cell Signaling Technologies),
where appropriate.
Western blotting and subcellular fractionations
Western blotting was carried out as previously descri-
bed19. Nuclear/Cytoplasmic fractionations are described
in detail in Supplementary methods 1. cIAP1- and cIAP2-
speciﬁc antibodies were from Enzo (Exeter, UK). XIAP,
RIPK1, Acetylated-Lysine, HDAC1- and caspase 3-
speciﬁc antibodies were from Cell Signaling Technology
(Danvers, MA, USA). Caspase 8 antibody was from Alexis
Biochemicals (San Diego, CA, USA). FLIP antibody was
from Adipogen (San Diego, CA, USA). PARP antibody
was from eBioscience (San Diego, CA). FADD antibody
was obtained from BD Transduction Laboratories
(Franklin Lakes, NJ, USA). Ku70 and HSP90 antibodies
were from Santa Cruz Biotechnology (Dallas, Texas,
USA). Secondary horseradish peroxidase-conjugated
antibodies (Amersham, Buckinghamshire, UK) were
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used for detection on a G-Box digital developer (Syngene.
Cambridge, UK).
Flow cytometry
Analysis of cell-surface TNFR-1 expression was car-
ried out on a BD Facs Caliber ﬂow cytometer using the
Cell Quest Pro software (BD Biosciences, San Diego,
CA, USA), and cells stained using Phycoerythrin-
conjugated anti-TNFR1 antibody (R&D Systems, Min-
neapolis, MN, USA) compared to an isotype control
antibody. Annexin-V/Propidium Iodide ﬂow cytometry
was carried out on a BD LSR-II ﬂow cytometer (BD
Biosciences, San Diego, CA, USA) using FITC-Tagged
Annexin-V (BD-Biosciences) and Propidium Iodide
(Sigma-Aldrich).
High-content Microscopy
High-content microscopy was carried out on an Array
Scan XTI high content microscope (Thermo Scientiﬁc)
using FITC-Tagged Annexin-V (BD-Biosciences) Propi-
dium Iodide (Sigma-Aldrich), and Hoescht Stain
(Invitrogen).
siRNA transfections
All siRNAs (SC, cIAP2, XIAP, FLIP (L, S&T), RIPK1,
Ku70) were obtained from Dharmacon (Chicago, IL,
USA), and transfections carried out using Lipofectamine
RNA iMAX (Life Technologies), as previously descri-
bed20. Sequences shown in Supplementary methods 2.
Immunoprecipitation
For complex-IIb immunoprecipitation cells were lysed
in CHAPS buffer (30 mM Tris pH 7.5, 150 mM NaCl, 1%
CHAPS). Anti-p18-capsase-8 antibody (1 μg, Santa
Cruz, CA) was conjugated to 30 μL Protein G Dyna-
beads (Invitrogen, Paisley, UK). For acetylated-lysine
immunoprecipitation, cells were lysed in RIPA buffer
and 1 μg of acetylated-lysine antibody (Cell Signaling
Technologies) was conjugated to beads. 750 μg of pro-
tein lysate was immunoprecipitated for 6 h at 4°C. IgG
isoytpe controls were purchased from Santa Cruz. Co-
Immunoprecipitation experiments were analysed by
Western Blotting.
Caspase 3/7 activity assay
Caspase 3/7 activity was assayed using Caspase-Glo®
3/7 assay according to manufacturer’s instructions (Pro-
mega, Madison, WI).
Cell viability assay
Cell viability was assessed by Cell Titre-Glo® assay
according to manufacturer’s instructions (Promega,
Madison, WI, USA).
In vivo xenograft study
All animal experiments were conducted in compliance
with institutional guidelines and authority regulations. For
in vivo anti-tumor efﬁcacy study 1 × 106 PC3 cells in 1:1
Matrigel:PBS were subcutaneously injected into male
Balb/c SCID mice, one tumor per mouse. After tumors
were established (volume ≥ 100 mm3), mice were treated
with Vehicle (Veh) (1% DMSO in Peanut Oil (IP) and 30%
Cyclodextrin (PO)), intraperitoneally with 20 mg/kg
TL32711, orally with 15mg/kg Entinostat (ENT), or with
the TL32711 and Entinostat combination. Tumor
volumes and animal weights were measured regularly
until study endpoint (volume ≥ 500mm3). Tumor tissues
and blood were harvested for further analysis.
Immunohistochemistry and Immunoﬂuorescence
Immunohistochemistry staining on FFPE xenograft tis-
sue for FLIP and cleaved-caspase-3 was carried out as
previously described21. FLIP antibody was obtained from
Abcam (Cambridge, England, UK) and used at a dilution
of 1:1000, cleaved caspase-3 antibody was obtained from
Cell-Signaling Technologies and used at a dilution of
1:200. Microscopy slides were digitally scanned using an
Aperio CS2 slide scanner (Leica Biosystems, Milton
Keynes, UK). Immunoﬂuorescence was carried out using
a Zeiss Apotome microscope. F4/80 antibody was
obtained from Biorad (CA, USA) and used at a dilution of
1:200, Cytokeratin-5 antibody was used at a dilution of
1:200, and ﬂuorescent labelled secondary antibodies from
Invitrogen (CA, USA) used at 1:1000. Mounting media
containing DAPI (Invitrogen) was used to ﬁx coverslips
and stain nuclei simultaneously.
TNFα ELISA
Human TNFα was quantiﬁed by human TNFα ELISA
(Abcam, Cambridge, UK), and murine TNFα (Abcam)
from mouse serum as-per manufacturer’s instructions.
Statistical Analysis
Experimental results were compared using a two-tailed
Students t-test, or Two-Way ANOVA with Bonferroni
Post-test, where appropriate. Experiments were carried
out in triplicate, values represent mean ± SEM. *p ≤ 0.05
**p ≤ 0.01 and ***p ≤ 0.001.
Results
IAP antagonists have rapid and potent on target activity in
prostate cancer cell lines
PC3, DU145 and VCaP cell lines were used throughout
this study as they represent CRPC22. VCaP cells are a truly
castrate-resistant model as, although they express
androgen receptor, they do not respond to androgen-
deprivation therapy in vitro or in vivo23. Core components
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of the TNFR1 apoptosis signaling pathway were proﬁled
at the protein level by Western blot (Fig. 1a) and ﬂow
cytometry (TNFR1; Fig. 1b). cIAP1 expression was high in
DU145 and VCaP, whereas cIAP2 expression was highest
in PC3 cells and absent in the VCaP model. XIAP
was expressed at a similar level in the three models.
Expression of the Complex-IIb adaptors RIPK1 and
FADD were similar across the models as was expression
of procaspase-3; however, procaspase-8 expression was
signiﬁcantly lower in the VCaP model. Notably, expres-
sion of both FLIP splice forms correlated with expression
of cIAP1 in the 3 cell lines. Similar levels of cell-surface
TNFR1 were detected in each cell line (Fig. 1b).
The bivalent IAP antagonist TL3271124 induced
degradation of cIAP1 in PC3, DU145 and VCaP cells
(Fig. 1c); a widely accepted pharmacodynamic (PD) bio-
marker of on-target activity for this class of agent25 and
conﬁrms potent on-target activity of TL32711 at nano-
molar concentrations. Of note, no consistent effect on
XIAP expression was observed. In timecourse studies,
rapid depletion of cIAP1 was observed in response to
TL32711 (Fig. 1d); cIAP2 downregulation was also
detected at early timepoints, but recovered to near control
levels after 3 h, consistent with reports of IAP antagonist-
induced activation of the non-canonical NFκB pathway
following cIAP downregulation and the requirement for
cIAP1 to mediate cIAP2 ubiquitination and degrada-
tion26–28. In contrast, XIAP levels remained relatively
unaffected by TL32711. Similar results were obtained with
the monovalent IAP antagonist ASTX660 (Fig. 1e–f).
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Fig. 1 IAP antagonists have rapid and potent on target activity in prostate cancer cell lines. a Western blot analysis of basal expression of
cIAP1, cIAP2, XIAP, FLIP(L), FLIP(S), Procaspase-8, RIPK1, FADD, Procaspase-3 and β-actin in PC3, DU145 and VCaP cell lines. b Flow cytometric analysis
of basal cell surface expression of TNFR1 in PC3, DU145 and VCaP cell lines compared to an IgG isotype control. c Western blot of cIAP1, cIAP2 and
XIAP expression following treatment with 0, 10, 1, 0.1, 0.1, 0.01 and 0.001 μM TL32711 in PC3, DU145 and VCaP cell lines for 24 h. d Western Blot of
cIAP1, cIAP2, and XIAP expression following 1, 3, 6, 12 and 24 h treatment with a clinically-achievable dose of 1 μM TL32711 in PC3 and DU145 cells. e
Western blot analysis of cIAP1, cIAP2 and XIAP expression following treatment with 0, 10, 1, 0.1, 0.1, 0.01 and 0.001 μM ASTX660 in PC3, and DU145
cell lines for 24 h. f Western Blot of cIAP1, cIAP2, and XIAP expression following 1, 3, 6, 12 and 24 h treatment with 1 µM ASTX660 in PC3 and DU145
cell lines
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Prostate cancer cell lines are resistant to TL32711+ TNFα
combination
Following treatment with a clinically-achievable dose
1μM TL32711 for 3 h in the presence of 10 ng/mL
recombinant TNFα (to model a proinﬂammatory micro-
environment), formation of TNFR1 Complex-IIb was
observed in all cell lines as indicated by interaction
between caspase-8 and RIPK1 (Fig. 2a). Only in the PC3
model did formation of Complex-IIb correlate with
downstream activation of signiﬁcant levels of apoptosis
(Fig. 2b). TL32711 alone induced a small but consistent
increase in cell death in PC3 cells, although neither this
line nor DU145 secreted detectable levels of TNFα basally
or following IAP antagonist treatment as determined by
ELISA (Supplementary Figure 1). Recombinant TNFα
alone had no effect on cell death in any of the CRPC
models. These results were mirrored in cell viability
assays, with DU145 and VCaP cells exhibiting profound
resistance (over 80% cell viability relative to control in
response to 1μM TL32711 plus TNFα; Fig. 2c). Even in
the more sensitive PC3 model, ~60% cell viability relative
to control was observed in response to 1μM TL32711 in
combination with TNFα, and almost no activity with
TL32711 monotherapy was observed. Similar results were
obtained with ASTX660 (Supplementary Figure 2A-B).
Taken together, these ﬁndings suggest that, despite
efﬁcient formation of Complex-IIb, CRPC is inherently
resistant to IAP antagonist-induced apoptosis, even in the
presence of TNFα. As cIAP1 is rapidly and potently (1
nM) downregulated by both IAP antagonists in these
models, we assessed potential for resistance mediated by
the other 2 main IAPs, cIAP2 and XIAP, using RNAi.
Downregulation of either cIAP2 or XIAP (Fig. 2d) failed
to signiﬁcantly enhance sensitivity to TL32711/TNFα in
PC3 and DU145 cell lines, suggesting that other factors
are involved in mediating resistance to IAP antagonists in
CRPC.
Cytoplasmic FLIP(S) and nuclear FLIP(L) mediate resistance
of CRPC to IAP antagonist-induced apoptosis
FLIP is an inhibitor of caspase-8 activation29, and the
more resistant CRPC models (DU145 and VCaP) express
signiﬁcantly higher levels of both FLIP splice forms than
the more sensitive PC3 model (Fig. 1a). Moreover, we
have previously found that FLIP is frequently over-
expressed in CRPC6. We therefore assessed FLIP’s role in
mediating the observed resistance to IAP antagonists. In
all three models, simultaneously downregulating both
FLIP(L) and FLIP(S) by siRNA (FT) signiﬁcantly
enhanced cell death induction in response to TL32711/
TNFα (Fig. 3a), and these effects were reﬂected in
reductions in cell viability (Supplementary Figure 3).
Similar effects were observed with the monovalent IAP
antagonist, ASTX660 (Supplementary Figure 4). Notably,
simultaneous downregulation of FLIP(L) and FLIP(S)
with the dual splice form-targeted siRNA (FT) resulted in
signiﬁcant levels of apoptosis induction in the DU145
model (the model with highest FLIP levels) in the absence
of co-treatment with either IAP antagonist or TNFα,
indicating that this model is intrinsically FLIP-dependent.
Also, in PC3 cells, simultaneous downregulation of FLIP
(L) and FLIP(S) enhanced sensitivity to both TL32711
alone and TNFα alone, an effect also observed in DU145,
but not VCaP cells. Speciﬁc silencing of either the long
(FL siRNA) or the short (FS siRNA) splice form also
enhanced cell death induction in response to TL32711/
TNFα, although to a lesser extent than simultaneously
targeting both splice forms, indicating that both FLIP
splice forms mediate resistance (Fig. 3a).
Qualitative assessment of apoptotic cell death by PARP
cleavage conﬁrmed the results of the cell death and cell
viability assays, with enhanced PARP cleavage observed
after transfection with siRNA targeting both FLIP(L) and
FLIP(S) splice forms-in combination with TL32711/TNFα
in all three models (Fig. 3b). Transfection with the FLIP
(L)-speciﬁc siRNA also enhanced TL32711/TNFα-
induced PARP cleavage in all three cell lines, but to a
lesser extent than the dual-targeted siRNA, while the FLIP
(S)-speciﬁc siRNA enhanced TL32711/TNFα-induced
PARP cleavage in PC3 and DU145 cells, albeit to a lesser
extent than the FT and FL siRNAs. Despite the clear
enhancement of sensitivity to TL32711/TNFα in FLIP
siRNA transfected cells, there was a relative lack of
downregulation of FLIP(L) in cells transfected with either
the dual splice form targeting or selective FLIP(L) siRNA
in all three models (Fig. 3b). In contrast, FLIP(S) was
efﬁciently downregulated by both the FLIP(S)-speciﬁc and
FT siRNAs. The p43-cleavage product of FLIP(L), which
is generated when it heterodimerizes with procaspase-8 in
Complex IIb29, was depleted in FT and FL siRNA trans-
fected cells, suggesting that it is the pool of FLIP(L) which
can be recruited to Complex-IIb that is effectively tar-
geted by these siRNAs. Importantly, p43-FLIP was
detected in complex-IIb (along with FADD, RIPK1 and
FLIP(S); Fig. 3c), indicating that FLIP(L) is recruited to
this complex and processed by caspase-8; importantly,
p43-FLIP was not detected in complex-IIb in the FT
siRNA transfected cells.
The FLIP long (FLIP(L)) splice form has been reported
to possess nuclear import and export signals30; we
therefore assessed whether either the cytoplasmic or
nuclear pools of FLIP(L) were being targeted by the FL
and FT siRNAs. We found that it was the nuclear pool of
FLIP(L) that was downregulated (Fig. 3d), suggesting
(somewhat surprisingly) that it is this pool of FLIP(L),
which, along with the predominantly cytoplasmic FLIP(S),
mediates resistance to TL32711/TNFα in CRPC cells.
This conclusion was further supported by the ﬁnding that
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the nuclear export inhibitor Leptomycin-B reduced clea-
vage of FLIP(L) to p43-FLIP(L) (indicating that it abro-
gates recruitment of FLIP(L) to Complex-IIb) and
enhanced TL32711/TNFα-induced PARP cleavage
(Fig. 3e, Left) and caspase activation (Right).
Further support for the critical role of FLIP in mod-
ulating CRPC resistance to TL32711/TNFα was obtained
using PC3 cell lines stably overexpressing wild-type FLIP
(L), wild-type FLIP(S), or F114A mutant FLIP(S) (Fig. 3f,
Right), which we have previously demonstrated binds
inefﬁciently to FADD and therefore fails to prevent
procaspase-8 homodimerization and activation at FADD-
dependent complexes31. We found that overexpression of
either wild-type FLIP protein, but not the F114A FLIP(S)
mutant protected PC3 cells against TL32711/TNFα-
induced cell death (Fig. 3f); this conﬁrms the criticality of
the FLIP/FADD interaction within Complex-IIb for FLIP’s
ability to confer resistance.
Entinostat downregulates FLIP and overcomes resistance
to apoptosis induced by IAP antagonists
The second generation Class I-selective histone deace-
tylase (HDAC) inhibitor Entinostat has demonstrated
clinical activity in hormone-resistant Breast Cancer32. In
both the PC3 and DU145 CRPC models, we found that
Entinostat downregulated both FLIP(S) and FLIP(L)
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expression, whereas expression of IAPs was unaffected
(Fig. 4a). In the VCaP model, the effect of Entinostat on
FLIP was more modest (Fig. 4b). Notably, Entinostat
downregulated nuclear rather than cytoplasmic FLIP(L) in
the PC3 and DU145 models, although it had almost no
effect on nuclear FLIP(L) in the VCaP model (Fig. 4c).
FLIP(S) was again found to be predominantly expressed in
the cytoplasm and was downregulated by Entinostat.
Other components of Complex-IIb (procaspase-8 and
FADD) were expressed in the cytoplasm and were unaf-
fected by Entinostat treatment. In addition, FLIP down-
regulation was mediated at the post-transcriptional level,
as FLIP mRNA expression was not downregulated in
response to Entinostat; in fact, both FLIP(L) and FLIP(S)
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mRNAs were upregulated in the DU145 model (Supple-
mentary Figure 5).
The ability of Entinostat to enhance TL32711/TNFα-
induced cell death correlated with its ability to down-
regulate nuclear FLIP(L) and cytoplasmic FLIP(S), as
PC3 and DU145 models were sensitized to TL32711/
TNFα, whereas VCaP cells remained relatively resistant,
as assessed by cell death (Fig. 4d) and cell viability
(Fig. 4e) assays. Similar results were again obtained with
ASTX660 (Supplementary Figure 6). Furthermore, FLIP
downregulation was conﬁrmed to be critical for
Entinostat to overcome resistance to IAP antagonist
therapy: in PC3 cells overexpressing FLIP (either long or
short splice forms), Entinostat was unable to down-
regulate the exogenous FLIP proteins (Fig. 4f, Right),
consistent with our previous observations33. Subse-
quently PC3 cells overexpressing wild-type FLIP(S) or
FLIP(L) were resistant to the TL32711/TNFα and
Entinostat combination (Fig. 4f, Left). In contrast, PC3
cells overexpressing the FADD-binding mutant F114A
FLIP(S) had comparable sensitivity to the EV control
cells, conﬁrming the essentiality for FLIP binding to
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FADD in Complex-IIb to block cell death induction in
the context of Entinostat co-treatment.
Entinostat enhances apoptosis in response to IAP
antagonists via Ku70, RIPK1 and caspase-8
Given the multiple potential modes of action of HDAC
inhibitors34,35, we further explored the mechanism by
which Entinostat enhanced sensitivity to TL32711/TNFα.
HDAC inhibition in colorectal cancer cells leads to the
acetylation of the DNA damage repair protein Ku70,
leading to the disruption of a stabilizing interaction
between FLIP and Ku70, resulting in ubiquitin-mediated
FLIP degradation33. To assess the role of Ku70 in reg-
ulating FLIP expression in prostate cancer cells, we ﬁrst
conﬁrmed that Entinostat enhanced acetylation of Ku70
(Fig. 5a, Left) whilst also depleting FLIP expression in PC3
and DU145 cells (Fig. 5a, Right); subsequently, we
demonstrated that, similar to Entinostat, Ku70 down-
regulation using siRNA caused depletion of nuclear but
not cytoplasmic FLIP(L), although, unlike Entinostat, it
had no effect on cytoplasmic FLIP(S) (Fig. 5b). These
results suggest that nuclear FLIP(L) is stabilized by Ku70
in prostate cancer cells and that Ku70 acetylation in
response to Entinostat results in downregulation of this
subcellular fraction of FLIP(L).
IAP antagonists have been shown to induce cell death
through Complex-IIb via two RIPK1-dependent
mechanisms: caspase-8-mediated apoptosis and RIPK3-
mediated necroptosis36. As expected given the observed
formation of RIPK1/procaspase-8 complex in response to
TL32711/TNFα (Figs 2a and 3c), RIPK1 siRNA sig-
niﬁcantly protected CRPC cells against cell death induced
by TL32711/TNFα, both with and without Entinostat pre-
treatment (Fig. 5c). Small molecule inhibition of RIPK1 or
RIPK3 kinase activity or MLKL oligomerisation (with
Necrostatin-1, GSK’840 or Necrosulfonamide, respec-
tively) failed to protect against TL32711/TNFα and Ent/
TL32711/TNFα-induced cell death (Fig. 5d). The pan-
caspase inhibitor z-VAD-fmk completely protected
against apoptosis and reduction in viability induced by
Entinostat in combination with TL32711/TNFα (Fig. 5e).
PC3 cells deﬁcient in caspase-8 (PC3-C8 CRISPR) were
protected against TL32711/TNFα with and without
Entinostat, conﬁrming that the cell death induced is
caspase-8-dependent apoptosis in both the absence and
presence of the HDAC inhibitor (Fig. 5f). Collectively
these results indicate that the scaffold function, but not
the kinase activity of RIPK1 is essential for the apoptotic
cell death induced by this combination in CRPC.
Macrophage-derived TNFa and in vivo- efﬁcacy of TL32711
To more closely mimic the proinﬂammatory tumor
microenvironment (TME), we assessed the ability of
macrophage-derived TNFα to induce apoptosis in the
context of IAP inhibition. Differentiation of human THP-
1 monocytic cells into M1-like macrophages signiﬁcantly
increased their secretion of TNFα (Fig. 6a). PC3 cells co-
treated with M1 THP-1 conditioned media were sensitive
to TL23711 alone, and this sensitivity was greatly
increased in PC3 cells pre-treated with Entinostat
(Fig. 6b). Importantly, use of a TNFα-neutralizing anti-
body demonstrated that the cell death induced in the
presence of M1 THP-1 conditioned media was TNFα-
dependent.
The strategy of using Entinostat to overcome resistance
of CRPC to IAP antagonists was further explored in a PC3
xenograft study (Fig. 6c). In support of our in vitro ﬁnd-
ings, co-treatment with Entinostat and TL32711 retarded
tumor growth more than treatment with either agent
individually. Moreover, this combination was well toler-
ated (Fig. 6d). Depletion of cIAP1 in the TL32711 and
combination treatment groups demonstrated TL32711
on-target activity (Fig. 6e). Moreover, immunohis-
tochemistry analyses conﬁrmed FLIP depletion in
Entinostat-treated groups and increased levels of cleaved
caspase-3 (a marker of apoptosis) in the combination-
treated group (Fig. 6f). The presence of macrophages in
close proximity to the engrafted tumor cells was con-
ﬁrmed by immunoﬂuorescent microscopy (Fig. 6g); with
positive staining for the murine-macrophage marker F4/
8037 evident in all treatment groups. Such macrophages
may act as the source of murine-derived TNFα detected
in the serum of these mice, as quantiﬁed by ELISA in
Fig. 6h. Notably, Entinostat, but not TL32711, sig-
niﬁcantly enhanced TME (murine)-derived TNFα, sug-
gesting a further mechanism by which Entinostat can
enhance sensitivity to IAP antagonists (Fig. 6h).
Discussion
With chronic inﬂammation often being cited as a key
driver of prostate tumorigenesis and disease progression1,
high levels of circulating TNFα observed in CRPC
patients3, and high intra-tumoral expression of TNFα and
TNFR1 cited as being associated with poor clinical out-
comes38, the potential for exploiting the pro-death activity
of TNFα was investigated. We hypothesized that inhibit-
ing IAPs would cause TNFα to induce cell death, thus
providing a therapeutic rationale for using IAP antago-
nists in proinﬂammatory CRPC.
Both bivalent (TL32711) and monovalent (ASTX660)
IAP antagonists were observed to have rapid and potent
on-target effects; however, although each of the CRPC
lines formed the cell death-inducing Complex-IIb these
cell lines were relatively (PC3) or totally (DU145, VCaP)
resistant to apoptosis induced by IAP antagonists alone
and when co-treated with TNFα or macrophage condi-
tioned media to mimic a proinﬂammatory TME. TL32711
has been reported to be cIAP1-selective, whereas
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ASTX660 inhibits both cIAP1 and XIAP24,39. However,
RNAi-mediated depletion of either cIAP2 or XIAP failed
to sensitize the CRPC models to TL32711, and cIAP2
depletion failed to enhance response to ASTX660 (not
shown), ruling out IAP redundancy as a mechanism of
resistance.
The caspase-8 regulator FLIP has been previously
shown by our group to be overexpressed in CRPC6. In
Complex-IIb, FLIP(L)/procaspase-8 heterodimers are
partially processed (to p43-FLIP(L) and p41/p43-caspase-
8), and this heterodimer has enzymatic activity but cannot
initiate cleavage of executioner procaspases and so does
not promote apoptosis induction. When FLIP(S) hetero-
dimerizes with procaspase-8 in Complex-IIb, the
heterodimer has no enzymatic activity and procaspase-8
cleavage is completely blocked, inhibiting apoptosis, but
also potentially promoting necroptosis as RIPK1 is also
not cleaved40. We found that while selective RNAi-
mediated depletion of either FLIP(L) or FLIP(S) enhanced
cell death induced by IAP antagonists, depletion of both
splice forms was required for the maximal induction of
cell death. Notably, we found that cytoplasmic FLIP(L)
was highly stable in CRPC cells, with no depletion up to
24 h after siRNA transfection (reported half-life ~3 h41);
the reason for this hyper-stability is currently under
investigation. However, nuclear FLIP(L) was effectively
depleted, and its downregulation along with down-
regulation of the predominantly cytoplasmic FLIP(S) was
PC3
Con TL+TNFα Ent Ent+TL+TNF
0
20
40
60
80 EV
C8 CRISPR
***
***
%
 A
nn
ex
in
 V
/P
I p
os
iti
ve
PC3
Con TL+TNFα Ent Ent+TL+TNF
0
20
40
60
80 siSC
siRIPK1
***
***
%
 A
nn
ex
in
 V
/P
I p
os
iti
ve
E
C
RIPK1
β-acn
siS
C
siR
IP
K1
Con Ent+TL+TNF
0
10
20
30
40
Con
z-VAD-fmk
PC3
*
%
 A
nn
ex
in
-V
/P
I p
os
iti
ve
PC3
0 1.0 2.5
0
20
40
60
80
100
120 CON
z-VAD-fmk
TL32711+TNF
z-VAD-fmk TL+TNF
***
***
***
[Entinostat μM]
%
 V
ia
bl
e 
C
el
ls
EV C8
Procaspase-8
β-acn
F
A
IB
: K
u7
0
- + - + - + -/+ 2.5μM Ent
PC3 DU145 VCaP
Ku70
FLIP(L)
FLIP(S)
Ac-H4
β-acn
PC3
Ku70
HSP90
siK
u7
0
DU145
FLIP(L)
FLIP(S)
B
PC3
- +- +     -/+ 2.5μM Ent-
DU145
VCaP
SC
R
EN
T
DM
SO
siK
u7
0
SC
R
EN
T
DM
SO
siK
u7
0
siS
C
EN
T
DM
SO
siK
u7
0
siS
C
EN
T
DM
SO
cytoplasmic nuclear cytoplasmic nuclear
PARP
70 kDa
55 kDa
26 kDa
42 kDa
12 kDa
70 kDa
55 kDa
26 kDa
119 kDa
90 kDa
PC3
Con TL+TNFα Ent Ent+TL+TNF
0
50
100
150
CON
RIPK1i
RIPK3i
MLKLi
n.s.
%
 V
ia
bl
e 
C
el
ls
PC3
Con TL+TNFα Ent Ent+TL+TNF
0
10
20
30
40
50
CON
RIPK1i
RIPK3i
MLKLi
n.s.
%
 A
nn
ex
in
 V
/P
I p
os
iti
ve
D
Fig. 5 Entinostat enhances apoptosis in response to IAP antagonists via Ku70, RIPK1 and caspase-8. a Western blot of Ku70 in PC3, DU145
and VCaP cells following immunoprecipitation with anti-acetylated Lysine (AcK) or IgG isotype control antibody after 24 h treatment with 2.5 µM
Entinostat(Ent) (Left). Right: Western blot of FLIP, Ku70, Hyperacetylated Histone4 (Ac-H4) in PC3, DU145 and VCaP cells treated for 24 h with 2.5 µM
Entinostat (Ent). b Western blot of FLIP, Ku70 and HSP90 and PARP in nuclear and cytoplasmic fractions from PC3 and DU145 cells treated for 24 h
with 2.5 μM Entinostat(ENT) or transfected with 20 nM scrambled control(SC) or Ku70 siRNA. c Annexin-V/PI ﬂow cytometry analysis of PC3 cells
transfected for 24 h with 20 nM scrambled control (SC) or RIPK1 siRNA followed by 24 h of 2.5 µM Entinostat(Ent) and a further 24 h with 1 µM
TL32711 and 10 ng/mL TNFα combination. Western blot analysis of RIPK1 and β-actin in PC3 cells treated with 10 nM SC or RIPK1 siRNA. d Annexin-V/
PI ﬂow cytometry (Left)and cell viability assay (Right) in PC3 cells pre-treated for 1 h with 20 µM Necrostatin-1 (RIPK1 kinase inhibitor), GSK’840 (RIPK3
kinase inhibitor Necrosulfonamide (MLKL inhibitor) followed by pre-treatment for 24 h with 2.5 µM Entinostat(Ent) and a further 24 h with 1 µM
TL32711 and 10 ng/mL TNFα combination. e Annexin-V/PI ﬂow cytometry (Left) and cell viability assay (Right) in PC3 cells pre-treated for 1 h with 20
µM z-VAD-fmk followed by pre-treatment for 24 h with 2.5 µM Entinostat(Ent) and a further 24 h with 1 µM TL32711 and 10 ng/mL TNFα
combination. f Annexin-V/PI ﬂow cytometry analysis of PC3 empty vector(EV) and procaspase-8(C8) CRISPR cells following pre-treatment for 24 h with
2.5 µM Entinostat(Ent) and a further 24 h with 1 µM TL32711 and 10 ng/mL TNFα combination. *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001
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sufﬁcient to promote apoptosis in response to IAP
antagonists. This suggests that in CRPC at least, the
nuclear pool of FLIP(L) is more important than the
cytoplasmic pool for blocking Complex-IIb-mediated cell
death. This was further supported by the observation that
the nuclear export inhibitor Leptomycin-B enhanced cell
death induced by TL32711/TNFα.
HDAC inhibitors have a wide range of anti-cancer
activities primarily through their abilities to modulate
gene expression via acetylation of histones and non-
histone proteins35,42. Because of these activities, HDAC
inhibitors are being pre-clinically and clinically investi-
gated in a number of cancers in combination with other
agents, most notably immune oncology agents43,44. We
and others have previously demonstrated that HDAC
inhibitors downregulate FLIP expression by both tran-
scriptional and post-transcriptional mechanisms33,45,46.
The Class I-selective HDACi Entinostat has been given
Breakthrough Therapy status by the FDA after showing
promising results in the treatment of aromatase inhibitor-
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mL TNFα neutralising antibody. c Tumor volume analysis of PC3 xenografts implanted into SCID-mice treated with Vehicle(Veh), 20 mg/kg TL32711,
15 mg/kg Entinostat(ENT) or TL32711 and Entinostat combination(schedule as indicated; E- Entinostat, T- TL32711). d Mouse weights for duration of
xenograft study. *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001. e Western blot analysis of cIAP1 expression in PC3 cells pre-implantation (in vitro) and three
individual PC3 xenograft tumor lysate 24 h following ﬁnal dose of Vehicle (Veh), Entinostat(Ent), TL32711 or Combination(Combo). f
Immunohistochemical analysis of FLIP (Left), and cleaved caspase-3 (Right) expression in PC3 xenograft tumors from mice 24 h following ﬁnal dose of
Vehicle, Entinostat, TL32711 or Combination. Representative IHC images of 3 regions of 3 tumors collected per treatment group. g
Immunoﬂurorescent microscopy of the murine macrophage marker F4/80, cytokeratin (CK)-5 epithelial cell marker, and DAPI-stained nuclei in PC3
xenograft tissue. Scale bar represents 100 μm. h Murine TNFα ELISA quantifying murine TNFα present in the serum of mice 24 h following ﬁnal dose
of Vehicle (Veh), Entinostat (Ent), TL32711 or Combination(Combo). Data represents pooled values in duplicate from 3 mice per treatment group.
*p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001
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resistant breast cancer32. Because of this activity in a
hormone-resistant disease setting, we explored Entinostat
as a clinically relevant approach for targeting FLIP
expression in CRPC to overcome resistance to IAP
antagonists. Entinostat was observed to downregulate
nuclear FLIP(L) and cytoplasmic FLIP(S) protein expres-
sion via post-transcriptional mechanisms in two out of
three CRPC models and subsequently sensitize these
models to IAP antagonist therapy in vitro and in vivo.
Mechanistically, this appears to be due to Entinostat-
induced acetylation of Ku70, a protein best characterized
as a key component of the DNA damage repair machin-
ery47, which we have previously shown to inhibit FLIP
ubiquitination and degradation in an acetylation-
dependent manner33. In prostate cancer cells, Ku70 was
found to be acetylated in response to Entinostat, and
siRNA-mediated Ku70 depletion resulted in down-
regulation of nuclear but not cytoplasmic FLIP(L). Gong
et al. proposed a similar mechanism by which HDAC
inhibition induces an acetylation-dependent disruption of
the Ku70:FLIP complex48. In addition, FLIP(L)/(S)
downregulation following Entinostat treatment may also
be caused by activation of JNK activity49. JNK could
subsequently activate the E3-ubiquitin ligase ITCH, which
has previously been reported to promote FLIP degrada-
tion via the ubiquitination-proteasome system (UPS)50.
Entinostat-mediated enhancement of TL32711/TNFα-
induced cell death was also determined to be caspase-
dependent (i.e., not necroptotic) and, more speciﬁcally,
caspase-8-dependent. We also demonstrated that the cell
death induced by TL32711/TNFα in the presence and
absence of Entinostat was dependent on RIPK1 and FLIP’s
ability to interact with the key Complex-IIb adaptor pro-
tein FADD. Thus, the sensitizing effects of Entinostat are
clearly due to its effects on FLIP rather than other effects
of Class-I HDAC inhibition. In conclusion, these results
show that although IAP antagonists promote formation of
Complex-IIb in proinﬂammatory models of CRPC, these
complexes fail to activate cell death because of the co-
recruitment of FLIP. However, the inhibitory effects of
FLIP can be overcome using the clinically relevant HDAC
inhibitor Entinostat, suggesting that strategies combining
this agent with IAP antagonists (particularly better toler-
ated next-generation antagonists such as ASTX660) may
be effective in proinﬂammatory CRPC.
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